SLC5A2 and type 2 diabetes mellitus: The introduction of SGLT2 inhibitors (SGLT2is) has revolutionized the management of type II diabetes mellitus (NIDDM), achieving, in addition to an outstanding attenuation of all metabolic derangements, remarkable cardiovascular and renal protection.